Related Experiment Video

Updated: May 6, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

25.5K

Correlation between lipoprotein(a) and recurrent ischemic events post-cerebral vascular stent implantation

Nan Zhang1, Kaili Shi1, Shuyin Ma1

  • 1Department of Neurology, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710004, China.

Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association
|July 22, 2024
PubMed

Insights

Elevated Lipoprotein(a) (Lp[a]) levels significantly increase the risk of recurrent ischemic events in patients with intracranial or extracranial artery stents. This finding highlights Lp[a] as a key predictor for adverse outcomes post-stenting.

Area of Science:

  • Cardiovascular Medicine
  • Neurology
  • Clinical Research

Background:

  • The role of Lipoprotein(a) (Lp[a]) in recurrent ischemic events after stenting is not fully understood.
  • Investigating Lp[a] is crucial for managing patients with stented arteries.

Purpose of the Study:

  • To determine the association between elevated Lp(a) levels and ischemic events in patients who underwent artery stenting.
  • To identify Lp(a]) as a potential risk factor in this patient cohort.

Main Methods:

  • A cohort of 553 patients receiving intracranial or extracranial artery stents was analyzed.
  • Cox regression and nomogram models were employed to assess Lp(a) impact and predict outcomes.
  • Postoperative ischemic events were meticulously followed up.

Main Results:

  • 19.3% of patients experienced ischemic outcomes, with higher rates in the elevated Lp(a) group (>30 mg/dL).
  • Elevated Lp(a) was associated with a 1.811-fold increased likelihood of ischemic events.
  • Each 1 mg/dL increase in Lp(a) correlated with a 1.008-fold rise in recurrence risk.

Conclusions:

  • Lipoprotein(a) elevation is a significant independent risk factor for ischemic events in stented patients.
  • Lp(a) levels should be considered in risk stratification for patients undergoing artery stenting.
  • Further research may explore targeted therapies for elevated Lp(a) to prevent recurrent events.
Abstract

Keywords:
AtherosclerosisIschemic eventLipoprotein(a)Predictive modeStent implantation

More Related Videos

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.3K
Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia07:25

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Published on: September 22, 2020

3.4K

Related Concept Videos

Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.1K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
893
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
452
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
502
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
2.5K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
747